Dr. Pierre L. Triozzi
Claim this profileWake Forest University Health Sciences
Studies Skin Cancer
Studies Cutaneous Melanoma
6 reported clinical trials
16 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
BRAF positive
2Cutaneous Melanoma
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Pierre L. Triozzi is currently running
Tuvusertib + Avelumab
for Merkel Cell Skin Cancer
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.
Recruiting1 award Phase 210 criteria
Tazemetostat + Dabrafenib + Trametinib
for Melanoma
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma.
Recruiting1 award Phase 1 & 224 criteria
More about Pierre L. Triozzi
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Pierre L. Triozzi has experience with
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
- Pembrolizumab
- Nivolumab
- Ipilimumab
- Therapeutic Conventional Surgery
Breakdown of trials Pierre L. Triozzi has run
Skin Cancer
Cutaneous Melanoma
Melanoma
Merkel Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pierre L. Triozzi specialize in?
Pierre L. Triozzi focuses on Skin Cancer and Cutaneous Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Pierre L. Triozzi currently recruiting for clinical trials?
Yes, Pierre L. Triozzi is currently recruiting for 3 clinical trials in Winston-Salem North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Pierre L. Triozzi has studied deeply?
Yes, Pierre L. Triozzi has studied treatments such as Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide, Pembrolizumab.
What is the best way to schedule an appointment with Pierre L. Triozzi?
Apply for one of the trials that Pierre L. Triozzi is conducting.
What is the office address of Pierre L. Triozzi?
The office of Pierre L. Triozzi is located at: Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157 United States. This is the address for their practice at the Wake Forest University Health Sciences.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.